Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report
Purpose Basal cell carcinoma (BCC) is one of the most common skin cancers. Most BCCs can be treated with surgery excision. For advanced BCC unsuitable for curative surgery, the combination of radiotherapy and Hedgehog pathway inhibitors (HHI) are effective systemic treatment options. However, there...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2462783 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206928897212416 |
|---|---|
| author | Zhuren Ruan Chen Zhao Longshan Li Xianghui Li Zhijian Yao Gao Wei |
| author_facet | Zhuren Ruan Chen Zhao Longshan Li Xianghui Li Zhijian Yao Gao Wei |
| author_sort | Zhuren Ruan |
| collection | DOAJ |
| description | Purpose Basal cell carcinoma (BCC) is one of the most common skin cancers. Most BCCs can be treated with surgery excision. For advanced BCC unsuitable for curative surgery, the combination of radiotherapy and Hedgehog pathway inhibitors (HHI) are effective systemic treatment options. However, there is a scarcity of evidence-based guidelines for the management of patients with advanced or metastatic BCC, particularly those who develop resistance to HHI therapy.Materials and methods We report the case of a patient with advanced BCC of the head and neck, which originated from a nevus sebaceous.Results The patient initially responded well to sonidegib, an HHI, but resistance emerged within a month. We then modified the systemic therapy to include a combination of radiotherapy and the anti-PD-1 agent sintilimab.Conclusions This adjusted treatment regimen led to effective long-term clinical responses without significant adverse events. |
| format | Article |
| id | doaj-art-23d713414c204853a97c8ac2804be795 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-23d713414c204853a97c8ac2804be7952025-02-07T00:46:47ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2462783Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case reportZhuren Ruan0Chen Zhao1Longshan Li2Xianghui Li3Zhijian Yao4Gao Wei5Department of Dermatology and Venereology, the First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Dermatology and Venereology, the First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Dermatology and Venereology, the First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Dermatology and Venereology, the First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Dermatology and Venereology, the First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Dermatology and Venereology, the First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaPurpose Basal cell carcinoma (BCC) is one of the most common skin cancers. Most BCCs can be treated with surgery excision. For advanced BCC unsuitable for curative surgery, the combination of radiotherapy and Hedgehog pathway inhibitors (HHI) are effective systemic treatment options. However, there is a scarcity of evidence-based guidelines for the management of patients with advanced or metastatic BCC, particularly those who develop resistance to HHI therapy.Materials and methods We report the case of a patient with advanced BCC of the head and neck, which originated from a nevus sebaceous.Results The patient initially responded well to sonidegib, an HHI, but resistance emerged within a month. We then modified the systemic therapy to include a combination of radiotherapy and the anti-PD-1 agent sintilimab.Conclusions This adjusted treatment regimen led to effective long-term clinical responses without significant adverse events.https://www.tandfonline.com/doi/10.1080/09546634.2025.2462783Basal cell carcinomahedgehog pathway inhibitorsradiotherapyimmunotherapy |
| spellingShingle | Zhuren Ruan Chen Zhao Longshan Li Xianghui Li Zhijian Yao Gao Wei Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report Journal of Dermatological Treatment Basal cell carcinoma hedgehog pathway inhibitors radiotherapy immunotherapy |
| title | Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report |
| title_full | Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report |
| title_fullStr | Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report |
| title_full_unstemmed | Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report |
| title_short | Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report |
| title_sort | hedgehog pathway inhibitors hhi combined with radiotherapy and immunotherapy for advanced basal cell carcinoma a case report |
| topic | Basal cell carcinoma hedgehog pathway inhibitors radiotherapy immunotherapy |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2025.2462783 |
| work_keys_str_mv | AT zhurenruan hedgehogpathwayinhibitorshhicombinedwithradiotherapyandimmunotherapyforadvancedbasalcellcarcinomaacasereport AT chenzhao hedgehogpathwayinhibitorshhicombinedwithradiotherapyandimmunotherapyforadvancedbasalcellcarcinomaacasereport AT longshanli hedgehogpathwayinhibitorshhicombinedwithradiotherapyandimmunotherapyforadvancedbasalcellcarcinomaacasereport AT xianghuili hedgehogpathwayinhibitorshhicombinedwithradiotherapyandimmunotherapyforadvancedbasalcellcarcinomaacasereport AT zhijianyao hedgehogpathwayinhibitorshhicombinedwithradiotherapyandimmunotherapyforadvancedbasalcellcarcinomaacasereport AT gaowei hedgehogpathwayinhibitorshhicombinedwithradiotherapyandimmunotherapyforadvancedbasalcellcarcinomaacasereport |